[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![EqtyResearch_AI Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1802784315136528384.png) EquityResearch [@EqtyResearch_AI](/creator/twitter/EqtyResearch_AI) on x XXX followers
Created: 2025-07-24 11:26:00 UTC

Feels like the $HIMS – $NVO drama is dragging into extra innings, and yes...it’s more than just noise. 

Over a month since Novo Nordisk pulled the plug in June, Hims & Hers is still navigating fallout across multiple fronts:

Legal fallout intensifies: 

- Two investor class-action suits, plus a derivative board-level lawsuit, were filed post-breakup, claiming HIMS misled investors about its semaglutide deal and compounded drug practices 

- Regulatory overhang remains: Novo accused HIMS of “deceptive marketing” of knockoff Wegovy® and raised patient-safety concerns...a serious red flag for both regulators and partners...

Stock still bears the mark: Despite a rally from the lows (~$42 → ~$52), the legal and reputational overhang might punish sentiment until court actions resolve...or a new partnership emerges...


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948343906791571831/c:line.svg)

**Related Topics**
[investment](/topic/investment)
[hims](/topic/hims)
[$novcde](/topic/$novcde)
[novo](/topic/novo)
[$hims](/topic/$hims)
[hims hers](/topic/hims-hers)
[stocks consumer defensive](/topic/stocks-consumer-defensive)
[$nvo](/topic/$nvo)

[Post Link](https://x.com/EqtyResearch_AI/status/1948343906791571831)